Jerome Alexandre
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
Year:
2026
Sarcomas frequently affect adolescent girls and young women, for whom future fertility is a critical concern. The urgency of initiating treatment—due to rapid tumor progression and the need for extensive diagnostic evaluation—often limits the window for fertility preservation prior to chemotherapy. However, emerging evidence indicates that gonadotoxicity is variable, and ovarian function may be preserved in a substantial number of cases. This observational cohort study evaluates the feasibility, timing, and clinical relevance of fertility preservation in young women treated for high‐grade sarcomas or desmoid tumors at Cochin Hospital, AP‐HP (Paris, France), with a focus on long‐term ovarian function and reproductive outcomes. Among 59 patients (median age at first oncology consultation, 24.3 years), 13 underwent oocyte or ovarian tissue cryopreservation before or early during treatment. Therapy regimens included alkylating and non‐alkylating chemotherapies, radiotherapy, or combinations thereof. At last follow‐up, 49 women were alive, and 27 had experienced relapse or progression. Among 26 patients assessed for post‐treatment ovarian function (median follow‐up 62 months), 77% resumed menstruation, 27% conceived naturally, 78% of those actively attempting pregnancy were naturally successful, and 19% gave birth. No patient used cryopreserved oocytes or ovarian tissue. One patient underwent fertility preservation after therapy. These results suggest that systematic fertility preservation may not be mandatory for all patients and that spontaneous ovarian function recovery is common. The observed pregnancy outcomes underscore the importance of personalized, patient‐centered fertility counseling based on tumor characteristics and treatment modalities.
Year:
2026
Year:
2026
Objective Advanced or recurrent endometrial carcinoma (EC) represents a significant clinical challenge. This study aimed to evaluate patient (age and comorbidities) and disease (histological subtypes and stages) characteristics, treatment patterns and survival outcomes in a real-world French healthcare setting. Methods and analysis In this national, multi-centre, retrospective observational cohort study, 200 patients with advanced or recurrent EC receiving first- or second-line chemotherapy during the year 2019 were analysed. Data collected included baseline characteristics, treatment regimens, real-world progression-free survival (rwPFS) and overall survival (OS). Results 127 and 73 were included in the first and second lines, respectively. Endometrioid carcinoma was the most represented histological subtype (62.0%). Patients in the first line, of whom 31.5% had FIGO (Fédération Internationale de Gynécologie Obstétrique) IVB disease, mainly received a combination of carboplatin and paclitaxel (78.0%), while 131 patients receiving second-line therapy were mainly administered anthracycline (54.2%). Median rwPFS and OS were, respectively, 8.5 and 13.2 months for patients receiving first-line therapy and 4.0 and 9.4 months for patients receiving second-line therapy. In Cox analyses, a diagnosis of carcinosarcoma, the presence of liver metastases and stage IVB disease were associated with worse survival outcomes for patients recieving first-line chemotherapy. Non-platinum chemotherapy and liver metastases were associated with poorer survival in patients receiving second-line chemotherapy. Conclusions This study highlights the landscape of metastatic EC treatment in a real-world French setting before the availability of PD1 inhibitors, emphasising the discrepancy between clinical trial data and real-world outcomes. It underscores the necessity for further real-world studies to complement clinical trials for a comprehensive understanding of metastatic EC management.
Year:
2025
Year:
2025
Rare ovarian cancer is a heterogeneous group of diseases with significant unmet medical needs and low chemotherapy sensitivity. In this context, the AcSé Pembrolizumab (NCT03012620) multicentric, non-randomized, phase II basket trial, assessing pembrolizumab monotherapy in rare tumors has been conducted. We report here the results from the rare ovarian cancer cohort. Primary outcome was the objective response rate (ORR) at week 12. Secondary endpoints included best ORR, clinical benefit rate, survival and safety. ORR at week 12 was 3.2% (95%CI, 0.4% to 11.2%), with one partial (PR) and one complete response (CR) in a patient with a teratoma with malignant transformation remaining in CR six years after initiating pembrolizumab. Stable disease (SD) was observed in 34% of patients, including one patient with carcinosarcoma maintaining a SD for 33 months. No new safety concerns and no deaths related to pembrolizumab were observed. Pembrolizumab in rare ovarian tumor subtypes showed limited ORR but promising long-term benefit in selected patients were observed.
Year:
2025
Purpose: No universal circulating biomarker exists for soft-tissue sarcoma (STS) and bone sarcoma. We report the translational relevance of a Droplet Digital PCR (ddPCR) assay allowing universal, specific, and dynamic detection of sarcoma-related hypermethylated ctDNA. Experimental Design: In silico analysis (The Cancer Genome Atlas/Gene Expression Omnibus datasets, n = 8,330) identified hypermethylated DNA positions in STS/bone sarcoma, unmethylated in nonsarcoma tissues or white blood cells releasing circulating plasma cell-free DNA (cfDNA). A ddPCR assay following bisulfite conversion of cfDNA was developed. The methylation signature performances were evaluated in independent in silico cohorts (The Cancer Genome Atlas/Gene Expression Omnibus, n = 1,342). The ddPCR assay was applied to cfDNA from healthy donors, patients with metastatic STS (METASARC cohort, n = 49, 13 histotypes), and patients with STS/bone sarcoma treated with neoadjuvant chemotherapy (NEOSARC cohort, n = 42, 10 histotypes). Results: A ddPCR assay targeting seven methylated genomic positions distinguished sarcoma samples from nonneoplastic mesenchymal and endothelial/liver tissues (AUC = 0.95; in silico validation set). Sensitivity allowed methylated DNA detection at a 1:1,000 dilution in genomic DNA, with a methylated allele frequency of 0.06%. ctDNA was positively detected in 45% of METASARC (22/49) and 74% of NEOSARC (31/42) patients, across all histotypes. ctDNA detection correlated with poor overall survival in METASARC patients with STS ( P = 0.039). Increasing ctDNA during neoadjuvant chemotherapy was associated with poor outcomes in NEOSARC (composite criteria with poor histologic response, radiological progression, or relapse within 6 months; P = 0.0095). Conclusions: This sensitive ddPCR assay for universally methylated ctDNA enables precise detection, prognostication, and real-time monitoring of tumor burden in patients with high-grade and advanced sarcoma, regardless of histotype or origin.
Year:
2025
Background Maintenance niraparib at an individualized starting dose (ISD) is established in platinum-sensitive recurrent ovarian cancer (PSROC). However, patients’ perspectives on the burden of prolonged maintenance therapy have not been reported in prospective trials or routine practice. Methods In the real-life multicenter NiQoLe study, patients with PSROC received ISD maintenance niraparib. The primary objective was to describe physician-reported adverse events (AEs) leading to treatment modification during the first 3 months. Secondary endpoints included patient-reported outcomes (symptomatic AEs using PRO-CTCAE, self-reported fatigue, and impact on daily activities/function using FACT-F) collected remotely weekly using a specifically designed electronic device. Results Most (80%) of 139 treated patients (median age = 70 years) began niraparib at 200 mg/day. Median treatment duration was 5.7 (range = 0.2-21.4) months. During the first 3 months, 86 patients (62%) required treatment modification (median = 27 days to modification). Physician-reported grade ≥3 niraparib-related AEs occurred in 34 patients (24%); 68 patients (49%) had treatment modification for AEs, predominantly thrombocytopenia. The most frequent patient-reported AEs (PRO-CTCAE) were fatigue, insomnia, constipation, and dry mouth. Self-reported AEs were severe in 66% of patients. At baseline, 33% of patients reported severe fatigue (FACT-F), which generally persisted during niraparib. Physicians systematically underestimated major patient-reported symptoms. Conclusions In routine practice, niraparib dose modification was often required during the first 3 months despite individualized dosing. Physicians underestimated the burden of fatigue and symptomatic AEs. Digital self-reporting of AEs is feasible, provides patient-centered information complementing physician-reported AEs, and allows fuller appreciation of toxicity in real-world studies. Clinical trial information NCT03752216
Year:
2024
Collaborators (16)
francois ghiringhelli
Université de Bourgogne
Laetitia COLLET
Université libre de Bruxelles
isabelle ray coquard
professor
-
Marc Righini
Head, full Professor
University Hospital of Geneva
Isabelle Mahé
head of department
Université Paris Cité
FREDERIQUE LAROUSSERIE
Université Paris-Saclay
philippe grenier
PROFESSOR
-
Benoit Blanchet
-
Frederikus A. Klok
Leiden University Medical Center
Camille Tlemsani
Université Paris Cité
Valerie Taly
CNRS Research Director
Université Paris Cité
Natacha Naoun
Institut Gustave Roussy
Grégoire Le Gal
Professor
University of Ottawa
françois cherifi
Médical Oncologiste
Centre François Baclesse Centre de Lutte Contre le Cancer
Diego Tosi
Institut de Recherche en Cancérologie de Montpellier
Pierre Laurent-Puig
Université Paris Descartes
Make your next move.
Prepare your application
Review drafts before you send them.